Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tulathromycin is a semi-synthetic macrolide antibiotic of the triamilide subclass, primarily used in veterinary medicine. It is indicated for the treatment and metaphylaxis of bovine respiratory disease (BRD) in cattle, swine respiratory disease (SRD) in pigs, and certain infections in sheep such as early-stage infectious pododermatitis (foot rot). Its mechanism of action involves selective binding to bacterial ribosomal RNA, inhibiting essential protein biosynthesis by stimulating dissociation of peptidyl-tRNA from the ribosome during translocation. This results mainly in bacteriostatic activity but can be bactericidal against some pathogens. Tulathromycin exhibits a long duration of action due to its extensive tissue distribution and slow elimination, especially accumulating in lung tissue[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tulathromycin.